[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350737-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-350737-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","liquid-biopsy-for-minimal-residual-disease-assessment-in-endometrial-and-cervical-cancers-molecular-rationale-clinical-evidence-and-translational-barriers","Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers - Molecular Rationale, Clinical Evidence, and Translational Barriers","","Endometrial and cervical cancers can recur from subclinical disease not detected by routine surveillance. This narrative review evaluates liquid biopsy for minimal residual disease (MRD) assessment and recurrence monitoring, focusing on molecular rationale, clinical evidence, and translational barriers. Persistent HPV circulating tumor DNA (ctDNA) in cervical cancer shows strong prospective validity, yet limited sensitivity prevents de-escalation based on negativity alone. For endometrial cancer, perioperative ctDNA is supported by meta-analytic prognostic data, while assay heterogeneity restricts readiness. Other liquid components remain exploratory and acting on results should await prospective trials proving outcome benefit.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/liquid-biopsy-for-minimal-residual-disease-assessment-in-endometrial-and-cervical-cancers-molecular-rationale-clinical-evidence-and-translational-barriers/350737/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/liquid-biopsy-for-minimal-residual-disease-assessment-in-endometrial-and-cervical-cancers-molecular-rationale-clinical-evidence-and-translational-barriers/350737.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main clinical goal of liquid biopsy in endometrial and cervical cancers?","Question",{"text":63,"@type":64},"To assess minimal residual disease (MRD) and monitor recurrence by detecting biologically persistent, subclinical malignant signals after treatment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why can’t cervical cancer treatment be safely de-escalated based only on negative HPV ctDNA results?",{"text":68,"@type":64},"Because although persistent HPV ctDNA detection is strongly associated with recurrence, the approach has moderate sensitivity and can produce false-negative results.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports the use of ctDNA in endometrial cancer, and what limits its readiness?",{"text":72,"@type":64},"Perioperative ctDNA shows prognostic support from an 11-study meta-analysis and additional cohorts, but assay heterogeneity and limited independent replication constrain clinical readiness.",{"name":74,"@type":61,"acceptedAnswer":75},"Which biomarkers are still considered exploratory rather than clinically ready?",{"text":76,"@type":64},"Circulating tumor cells, extracellular vesicles, microRNAs, tumor-educated platelets, and fragmentomics, along with broad pan-cancer plasma profiling, are described as mainly advanced-disease tools or preliminary evidence.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},350737,1790892227,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,104,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},"Comic",60,"comic",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},6,"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":55,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nLiquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers: Molecular Rationale, Clinical Evidence, and Translational Barriers  \nLudovica Pepe 1,2, Valeria Zuccalà 1, Walter Giuseppe Giordano 2, Giordana Di Mauro 3, Vincenzo Cianci 4, Cristina Mondello 4, Massimiliano Berretta 3, Vincenzo Fiorentino 1,2, * and Antonio Ieni 1, *  \nAcademic Editor: Panagiotis Christopoulos  \nReceived: 11 June 2026  \nRevised: 4 August 2026  \nAccepted: 8 August 2026  \nPublished: 10 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina, 98125 Messina, Italy; [ludopepe97@gmail.com](ludopepe97@gmail.com) (L.P.); [valeria.zuccala@unime.it](valeria.zuccala@unime.it) (V.Z.)  \n2 PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy; [waltergiordano1997g@gmail.com](waltergiordano1997g@gmail.com)  \n3 Division of Medical Oncology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy; [giordana.dimauro@studenti.unime.it](giordana.dimauro@studenti.unime.it) (G.D.M.); [mberretta@unime.it](mberretta@unime.it) (M.B.)  \n4 Section of Legal Medicine, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy; [enzocianci.1997@gmail.com](enzocianci.1997@gmail.com) (V.C.); [cristina.mondello@unime.it](cristina.mondello@unime.it) (C.M.)  \n* Correspondence: vincenzo.fiorentino@unime.it (V.F.); antonio.ieni@unime.it (A.I.)  \nAbstract  \nEndometrial and cervical cancers can recur from subclinical disease not evident on routine surveillance. This narrative review critically evaluates liquid biopsy for minimal residual disease (MRD) assessment and recurrence monitoring. Post-treatment human papillomavirus (HPV) circulating tumor DNA (ctDNA) in cervical cancer has the strongest disease-specific prospective evidence of clinical validity; persistent detection is strongly associated with recurrence, but moderate sensitivity and false-negative results do not support treatment de-escalation on negativity alone. With regard to endometrial cancer, perioperative ctDNA has prognostic support from an 11-study, 1298-patient meta-analysis and additional cohorts, although assay heterogeneity and limited independent replication constrain clinical readiness. Postoperative positivity generally shows stronger associations than preoperative detection. Cervicovaginal and urine DNA-methylation studies provide preliminary evidence for detecting established recurrence, especially local recurrence, but not prospective molecular lead time or clinical utility. Digital PCR, disease-specific fixed panels, tumor-informed assays, and error-corrected sequencing serve distinct settings; broad pan-cancer plasma profiling remains mainly an advanced-disease tool. Circulating tumor cells, extracellular vesicles, microRNAs, tumor-educated platelets, and fragmentomics remain exploratory. Liquid biopsy should remain an investigational adjunct until prospective trials show that acting on molecular findings improves outcomes.  \nKeywords: liquid biopsy; circulating tumor DNA; minimal residual disease; endometrial cancer; cervical cancer; HPV ctDNA; molecular profiling; recurrence surveillance; clinical validity; clinical utility  \n1. Introduction  \nEndometrial cancer (EC) and cervical cancer (CC) are major gynecologic malignancies with distinct epidemiological patterns, etiologic drivers, and clinical care pathways. CC  \nremains a major global health burden, particularly in low-and middle-income countries. By contrast, EC incidence and mortality are in","cbCainewXxYjUDv3","https://ap.wps.com/l/cbCainewXxYjUDv3","pdf",4209206,22,"English","# Introduction\n## Epidemiology and clinical context for MRD\n## HPV-driven cervical carcinogenesis and disparities\n## Endometrial cancer risk factors and rising burden\n# Liquid biopsy framework for MRD strategies\n## Comparative clinical and etiologic rationale (Figure 1)\n# MRD assessment evidence overview\n## Cervical cancer: HPV ctDNA validity and limits\n## Endometrial cancer: perioperative ctDNA meta-analytic support\n## Additional analytes and exploratory biomarkers\n# Translational barriers and clinical implications\n## Assay heterogeneity and replication constraints\n## When liquid biopsy should remain investigational","[{\"question\":\"What is the main clinical goal of liquid biopsy in endometrial and cervical cancers?\",\"answer\":\"To assess minimal residual disease (MRD) and monitor recurrence by detecting biologically persistent, subclinical malignant signals after treatment.\"},{\"question\":\"Why can’t cervical cancer treatment be safely de-escalated based only on negative HPV ctDNA results?\",\"answer\":\"Because although persistent HPV ctDNA detection is strongly associated with recurrence, the approach has moderate sensitivity and can produce false-negative results.\"},{\"question\":\"What evidence supports the use of ctDNA in endometrial cancer, and what limits its readiness?\",\"answer\":\"Perioperative ctDNA shows prognostic support from an 11-study meta-analysis and additional cohorts, but assay heterogeneity and limited independent replication constrain clinical readiness.\"},{\"question\":\"Which biomarkers are still considered exploratory rather than clinically ready?\",\"answer\":\"Circulating tumor cells, extracellular vesicles, microRNAs, tumor-educated platelets, and fragmentomics, along with broad pan-cancer plasma profiling, are described as mainly advanced-disease tools or preliminary evidence.\"}]","Liquid Biopsy for Minimal Residual Disease Assessment in Endometrial and Cervical Cancers - Molecular Rationale, Clinical Evidence, and Translational Barriers | PDF",1790090826,55,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00921887f888cc1db38d864da2959377.webp",983,1390,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17dc204318d67bc5d5c9046d538afc3f.webp",982,1388,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00eb7c580ab8dcc4ac2ce7eb3e078f10.webp",981,1387,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e21dd6a17a09e2d407c1275b8ec5eed6.webp",980,1385]